Komplementärmedizinische Therapie des Prostatakarzinoms

Zusammenfassung

Integrative Therapiekonzepte beim Prostatakarzinom können die Lebensqualität verbessern, zur Verlängerung der progressionsfreien Zeit beitragen. Zusätzlich können sie die Nebenwirkungen konventioneller Therapien reduzieren und die Ansprechrate erhöhen.

Der Beitrag gibt einen Überblick zu möglichen sinnvollen komplementären Methoden, deren Wirkweise und Evidenzgrad.

Abstract

In the case of prostate cancer, integrative therapeutic concepts can improve the quality of life and prolong the progression-free time. These concepts can also reduce the side effects of conventional therapies and increase the response rate.

The article presents an overview of possible conventional methods which are useful as well as the mode of action and the evidence level of such methods.

Schlüsselwörter

Prostatakarzinom - Komplementärmedizin

Keywords

Prostate cancer - complementary medicine

• Literatur

• 1 Turner EL, Lane JA, Metcalfe C. et al. Psychological distress and prostate specific antigen levels in men with and without prostate cancer. Brain Behav Immun 2009; 23: 1073-1078
• 2 Bastian PJ, Carter BH, Bjartell A. et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009; 55: 1321-1330
• 3 Klotz L, Zhang L, Lam A. et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-131
• 4 Shu-Seng Lei. et al. Clinical observations: A Chinese herbal formula for the treatment of pain as certain symptoms of cancer. The 1995 Toronto Conference of the World Association of Chinese Medicine 0
• 5 Beaches S. et al. The impact of age and diagnosis of prostate cancer treatment and survival. J Clin Oncol 2011; 29: 235-241
• 6 Murray K. Urological Hospital University of Cancers Medical Center. 0
• 7 Tsavachidou D, McDonnell TJ, Wen S. et al. Selenium and Vitamin E: Cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 2009; 101: 306-320
• 8 Kim HS. et al. A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): Results from the Shared Equal Access Regional Cancer Hospital Data Base. BJU Int 2011; 107 (06) 924-928
• 9 Danila DC, Morris MJ, de Bono JS. et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-1501
• 10 Jacob LM. et al. BPS Magazine. 2009; 2: 10-16
• 11 Blech J. „Übertherapie gehört dazu.“ Interview: Der Hamburger Urologe Hartwig Huland über Zweifel und Nutzen von Prostata-Operationen. Der Spiegel 2012; 30: 102-103
• 12 Ferlay J, Soerjomataram I, Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (05) E359-386
• 13 Klotz L, Zhang L. et al. Clinical results of long-term follow up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-131
• 14 Nielsen FH. Boron in human and animal nutrition. Plant and Soil 1997; 193: 199-208
• 15 Zhang ZF. et al. Boron is associated with decreased risk of human prostate cancer. FASEB J 2001; 15: A 1089
• 16 D’Amato RJ, Loughnan MS, Flynn E. et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad SCI USA 1994; 91: 4082-4085
• 17 Klotz L. et al. Utilizing metformin to enhance the efficacy of androgen-deprivation therapy in the treatment of prostate cancer. J Clin Oncol 2011; 29 (Suppl. 07) Abstract 22 0
• 18 Sharma V. et al. Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor: synergistic action of Quercetin and Curcumin. MOL Cell Endocrinol 2016; 431: 12-23
• 19 Gut R. et al. Statin use and risk of prostate cancer. J Clin Oncol 2010; 28: 2653-2659